Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Basile

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
American Journal of Hypertension|April 18, 2009
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trialBrent M Egan, Jan N Basile, Shakaib U Rehman, et al.
Journal of General Internal Medicine|July 9, 2014
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHATLinda B Piller, Lara M Simpson, Sarah Baraniuk, et al.
Hypertension (Dallas, Tex. : 1979)|August 10, 2016
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic SignificanceJerome L Fleg, Gregory W Evans, Karen L Margolis, et al.
Hypertension (Dallas, Tex. : 1979)|February 24, 2001
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Richard H. Grimm, Karen L. Margolis, Vasilios Papademetriou, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 19, 2008
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)William C Cushman, Charles E Ford, Paula T Einhorn, et al.
The New England Journal of Medicine|March 16, 2010
Effects of intensive blood-pressure control in type 2 diabetes mellitus, William C Cushman, Gregory W Evans, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Archives of Internal Medicine|January 30, 2008
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Jackson T Wright, Sonja Harris-Haywood, Sara Pressel, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen, Chuke E Nwachuku, Henry R Black, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 13, 2012
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialWilliam C Cushman, Barry R Davis, Sara L Pressel, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
American Journal of Hypertension|April 18, 2009
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trialBrent M Egan, Jan N Basile, Shakaib U Rehman, et al.
Journal of General Internal Medicine|July 9, 2014
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHATLinda B Piller, Lara M Simpson, Sarah Baraniuk, et al.
Hypertension (Dallas, Tex. : 1979)|August 10, 2016
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic SignificanceJerome L Fleg, Gregory W Evans, Karen L Margolis, et al.
Hypertension (Dallas, Tex. : 1979)|February 24, 2001
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Richard H. Grimm, Karen L. Margolis, Vasilios Papademetriou, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 19, 2008
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)William C Cushman, Charles E Ford, Paula T Einhorn, et al.
The New England Journal of Medicine|March 16, 2010
Effects of intensive blood-pressure control in type 2 diabetes mellitus, William C Cushman, Gregory W Evans, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Archives of Internal Medicine|January 30, 2008
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Jackson T Wright, Sonja Harris-Haywood, Sara Pressel, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen, Chuke E Nwachuku, Henry R Black, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 13, 2012
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialWilliam C Cushman, Barry R Davis, Sara L Pressel, et al.
Pageof 13